Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review-March 2024-www.financetom.com

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

Dec 30, 2024 2:42 PM

05:17 PM EST, 12/30/2024 (MT Newswires) -- Verastem ( VSTM ) said Monday that the US Food and Drug Administration accepted for review the new drug application for avutometinib in combination with defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer that received at least one systemic treatment and have KRAS mutation.

The FDA granted priority review to the new drug application and has set an action date of June 30, according to the company.

There are currently no approved treatments for low-grade serous ovarian cancer, Verastem ( VSTM ) added.

The new drug application is based on results from the Phase 2 Ramp 201 study that showed avutometinib plus defactinib had a substantial overall response rate.

Shares of the company were up 22% in recent after-hours activity.

Previous page： Google agrees $36 million fine for anti-competitive deals with Australia telcos Next page： First Andes Silver Raises $1.01 Million in First Tranche of Private Placement

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

First Andes Silver Raises $1.01 Million in First Tranche of Private Placement

Jul 17, 2025

07:21 AM EDT, 07/17/2025 (MT Newswires) -- First Andes Silver ( MSLVF ) after markets closed on Wednesday said it closed the first tranche of its previously announced non-brokered private placement, raising about $1.01 million. The company issued 10.17 million units at $0.10 each. Each unit is made up of one common share of the company and one-half of one...

GSK Says FDA Approved Prefilled Syringe Version of Shingles Vaccine

Jul 17, 2025

07:22 AM EDT, 07/17/2025 (MT Newswires) -- GSK (GSK) said Thursday that the US Food and Drug Administration has approved a prefilled syringe version of Shingrix, a vaccine for the prevention of shingles. The syringe removes the need to assemble vials before injection, simplifying vaccine administration, the company said. The prefilled syringe is licensed in the US for immunization of...

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

Jul 17, 2025

July 17 (Reuters) - US drugmakers Bristol Myers and Pfizer ( PFE ) said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program. Eligible patients will be able to buy the drug directly through the Eliquis 360 Support program from September 8 at a rate that is...